



11th November, 2022

The Manager - Listing **The National Stock Exchange of India Ltd.** Exchange Plaza, Plot No. C/1, G. Block Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Scrip Code: EMAMILTD The Manager - Listing **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 531162

Dear Sirs,

Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Presentation on Company's Performance update for the quarter ended 30th September, 2022.

The aforesaid information is also disclosed on the website of the company <u>www.emamiltd.in.</u>

This is for your information and records.

Thanking you,

Yours faithfully, For Emami Limited

<u>Ashok Purohit</u> Dy. Company Secretary & DGM- Legal (Encl. : As above)

BOROPLUS Parivaar ki Khushiyaan **Night Cream** For Dry Skin



BORO

PLUS

HEALTH

AYURVEDIC


Antiseptic Cream For Face, Hands & Body No Paraben

Dry Lips

FREE

BoroPlus

worth ₹65*



10 SUPER HERBS enriched with tulsi, chandan and haldi

BORO



Q2 & H1FY23 Performance Update 11th November 2022

AYURVEDIC

Antiseptic Cream


Q2 & H1 Revenue Growth



Dautiaulaus	Q2FY23	Growth (%)	H1FY23 Growth (%)			
Particulars	Over PY	3 year CAGR	Over PY	3 year CAGR		
Domestic Business	1%	8%	7 %	7 %		
International Business	17%	8%	30%	9%		
Consolidated Net Sales	4%	8%	10%	7 %		
Other Operating Income	-36%	-18%	0%	-8%		
Total Revenues	3%	7 %	10%	7 %		

- □ Helios Lifestyle Pvt. Ltd (The Man Company) became a Subsidiary of Emami Ltd w.e.f. 1st July'22 and contributed 3.5% to Consolidated Net Sales in Q2FY23
- Correction in Pain Management and Healthcare range on expected lines due to exceptionally high base in last year
- □ Net sales growth of 8% excluding Pain Management, Healthcare range and Helios in Q2FY23.

Modern Channels continue to perform well



Growth & salience to Domestic sales excluding Dermicool





Brand/ Business Performance analysis

Domestic brand wise & International sales performance analysis in Q2 & H1FY23

BoroPlus Range

- Sales grew by 17% in Q2 and by 14% in H1FY23
- Introduced new packaging for BoroPlus SOFT Ayurvedic Antiseptic Cream in tub format and 10 ml tub for BoroPlus Antiseptic Cream
- Roped in Bollywood superstar Akshay Kumar to endorse BoroPlus Antiseptic cream





6

Navratna Range

- Sales declined by 5% in Q2;
 - However, sales grew by 15% in H1FY23
- Continued BTL activations in H1FY23
 - 15+ vans covering 3000+ villages and
 600+ haats 12 lac+ samples distributed
 - 42000 salons covered across 60+ cities with 10 lac+ samples distributed
 - Participated in 19 fairs with ~47 lac samples distributed
- Digital activations on various platforms to build strong association of *Champi* with Navratna

Launched new campaign in Telugu, Kannada, Tamil & Malayalam for southern markets to target new users





Male Grooming Range

- Sales grew by 2% in Q2; 16% growth in H1FY23
- Fair and Handsome relaunched during the quarter
 - Packaging Revamp Vibrant/ clutter breaking packaging design - Clear differentiation between new and old pack on shelf
 - Communication Refresh (New TVC + Digital Amplification) –
 - New TVC communicating the key proposition of *Handsomegiri* i.e. looking and doing good at the same time
 - Digital Content Creation Voxpop Video
 - Website Revamp
 - Ecommerce & Social Media activation





Pain Management Range



- ⊳ Sales corrected by 13% in Q2 and by 21% in H1FY23
 - Delivered growth of 20% in Q2 and 26% in H1 this year compared to pre-COVID period (over Q2FY20 and H1FY20)
 - 3 year CAGR of 6% in Q2 and 8% in H1.
- Launched 100 ml SKU for Zandu Balm
- \triangleright Launched Zandu Fast Relief Gel in Aug'22 across channels
 - Endorsed by Dr. Ali Irani, ex-physio Team India



Healthcare Range



Sales corrected by 16% in Q2 and by 20% in H1FY23

- Delivered growth of 34% in Q2 and 39% in H1 this year compared to pre-COVID period (over Q2FY20 and H1FY20)
- 3 year CAGR of 10% in Q2 and 12% in H1.
- D2C portal Zanducare performing well despite drop in demand for immunity products
 - Digital First NPD's showing good traction;
 - Launched "Zandu Organic apple cider vinegar" powered with potent herbs like Ashwagandha, Garcinia and Saffron for myriad health benefits



Kesh King Range

- Sales declined by 10% in Q2 but grew by 3% in H1FY23
 - High base of 28% growth for last 2 years (Q2FY22 & Q2FY21)
 - 3 year CAGR of 14% in Q2FY23
- Launched new campaign for Kesh King Shampoo with Ali Fazal
 - Building Kesh King shampoo sachet through trade offers and sampling activity
- New launch Kesh King Onion Range performing well.







Digital first launches

emami

70ILS

NON STICKY HAIR OIL Organics

ALOE VERA

NO

SUITS ALL HAIR TYP

enugreek, Almond, Oliv

7 Oils in One Organics Zandu Organic Apple Cider Vinegar

Zandu Fast Relief Gel

New Launches





Launched in Aug'22 across channels

Launched in Sep'22

701LS

Organics

ALOE VERA

emami 70ILS

NON STICKY HAIP

Organi

RICE OI Hair Repair & No

NO

SUITS ALL HAIP

Almond, Olive, C Carrot, Walnut &

Organics

RICE OIL

MOLENE TIPES Annoed, Olive, Cossent Carrot, Walnut & Sesant

Organic apple cider vinegar powered with potent herbs like Ashwagandha, Garcinia and Saffron for myriad health benefits





New Campaigns





Digital Campaigns






International Business



- Sales grew by 17% in Q2 & by 30% in H1FY23
- Strong growth from MENA in Q2FY23
- CIS continued to grow despite disturbances
- Other SAARC markets including Nepal, Sri Lanka etc are showing signs of recovery despite continued macro-economic issues.





- SAARC South Asian Association for Regional Cooperation (Major countries Bangladesh, Nepal, Sri Lanka etc.)
- MENA Middle East & North Africa (Major countries KSA, UAE, Qatar, Oman, Kuwait, Bahrain etc.)
- CIS Commonwealth of Independent States (Major Countries Russia, Ukraine etc.)

Q2FY23 Profitability (Consolidated)



	Q2FY23				H1FY23			
Financials	₹ in crore	Growth	3 yr CAGR	Margins	₹in crore	Growth	3 yr CAGR	Margins
Revenues	814	3%	7%		1,587	10%	7%	
COGS	271	11%	11%	33.4%	558	19%	9%	35.1%
Gross Profit	542	0%	6%	66.6%	1,029	5%	5%	64.9%
A&P Spends	141	34%	10%	17.4%	278	29%	6%	17.5%
EBIDTA	195	-30%	0%	24.0%	369	-17%	4%	23.2%
PAT	180	-3%	23%	22.1%	253	-4%	23%	15.9%

Gross Margin decline due to inflationary pressure and favorable portfolio mix in PY 3 year CAGR EBIDTA growth of 4% in H1 despite aggressive investments behind brands

10

Q2FY23 Financial Analysis



Cost of Goods Sold (as a % of sales)

+230 bps



Staff Costs (as a % of sales)

+110 bps



Other Income

(₹ in Millions)

376


02FY22


420

02FY23

A&P Costs (as a % of sales)

+400 bps





H1FY23 Financial Analysis




17


Cost of Goods Sold (as a % of sales) +270 bps



Admin & Other Exp (as a % of sales) +210 bps



Staff Costs (as a % of sales) +0 bps



Other Income (₹ in Millions)



A&P Costs (as a % of sales) +260 bps 14.9% 14.9% HIFY22 HIFY23

(₹ in Millions)



Q2FY23 Consolidated Financials



Particulars	Q2FY23	%	Q2FY22	%	Growth	FY22	%		
Net Sales	8,073.6	99.2%	7,771.0	98.7%	3.9%	31,570.4	98.9%		
Other Operating Income	63.9	0.8%	100.2	1.3%	-36.2%	349.9	1.1%		
Revenue from Operations	8,137.5	100.0%	7,871.2	100.0%	3.4%	31,920.3	100.0%		
Materials Cost	2,715.7	33.4%	2,446.6	31.1%	11.0%	10,778.8	33.8%		
A&P	1,414.8	17.4%	1,053.2	13.4%	34.3%	5,229.0	16.4%		
Staff Cost	934.7	11.5%	820.7	10.4%	13.9%	3,177.7	10.0%		
Admin & Other Expenses	1,118.5	13.7%	778.9	9.9%	43.6%	3,211.1	10.1%		
EBIDTA	1,953.8	24.0%	2,771.8	35.2%	-29.5%	9,523.7	29.8%		
Other Income	419.9	5.2%	376.1	4.8%	11.6%	952.5	3.0%		
Interest	17.6	0.2%	7.8	0.1%	125.6%	50.7	0.2%		
Amortisation of acquired TM's/ brands	234.6	2.9%	602.7	7.7%	-61.1%	2,405.7	7.5%		
Depreciation/Amortisation of other assets	244.7	3.0%	236.1	3.0%	3.6%	942.1	3.0%		
PBT before Exceptional Items	1,876.8	23.1%	2,301.3	29.2%	-18.4%	7,077.7	22.2%		
Share of Profit /(loss) of associate	(21.6)	-0.3%	(38.4)	-0.5%	-43.8%	(145.8)	-0.5%		
Exceptional Items	-	0.0%	-	0.0%	0.0%	(51.8)	-0.2%		
РВТ	1,855.2	22.8%	2,262.9	28.7%	-18.0%	6,880.1	21.6%		
Тах	53.9	0.7%	410.4	5.2%	-86.9%	(1,486.6)	-4.7%		
PAT	1,801.3	22.1%	1,852.5	23.5%	-2.8%	8,366.7	26.2%		
Non controlling interest	(40.5)	-0.5%	(0.2)	0.0%	-100.0%	(23.2)	-0.1%		
Profit for the Period	1,841.8	22.6%	1,852.7	23.5%	-0.6%	8,389.9	26.3%		
Adjusted PAT	2,076.4	25.5%	2,455.4	31.2%	-15.4%	8,544.1	26.8%		
*Adjusted PAT = Reported PAT + Exceptional Items + Amortization of Kesh King & other brand related intangible assets. For FY22, it also excludes, MAT credit 18									

*Adjusted PAT = Reported PAT + Exceptional Items + Amortization of Kesh King & other brand related intangible assets. For FY22, it also excludes, MAT credit entitlement of previous years

H1FY23 Consolidated Financials



Particulars	H1FY23	%	H1FY22	%	Growth	FY22	%
Net Sales	15,703.2	98.9%	14,312.4	98.8%	9.7%	31,570.4	98.9%
Other Operating Income	167.4	1.1%	167.3	1.2%	0.1%	349.9	1.1%
Revenue from Operations	15,870.6	100.0%	14,479.7	100.0%	9.6%	31,920.3	100.0%
Materials Cost	5,576.6	35.1%	4,691.8	32.4%	18.9%	10,778.8	33.8%
A&P	2,777.8	17.5%	2,151.8	14.9%	29.1%	5,229.0	16.4%
Staff Cost	1,822.6	11.5%	1,665.7	11.5%	9.4%	3,177.7	10.0%
Admin & Other Expenses	2,006.6	12.6%	1,501.5	10.4%	33.6%	3,211.1	10.1%
EBIDTA	3,687.0	23.2%	4,468.9	30.9%	-17.5%	9,523.7	29.8%
Other Income	483.2	3.0%	483.3	3.3%	0.0%	952.5	3.0%
Interest	42.5	0.3%	14.2	0.1%	199.3%	50.7	0.2%
Amortisation of acquired TM's/ brands	874.1	5.5%	1,198.8	8.3%	-27.1%	2,405.7	7.5%
Depreciation/Amortisation of other assets	486.3	3.1%	470.0	3.2%	3.5%	942.1	3.0%
PBT before Exceptional Items	2,767.3	17.4%	3,269.2	22.6%	-15.4%	7,077.7	22.2%
Share of Profit /(loss) of associate	(65.3)	-0.4%	(53.6)	-0.4%	21.8%	(145.8)	-0.5%
Exceptional Items	-	0.0%	-	0.0%	0.0%	(51.8)	-0.2%
PBT	2,702.0	17.0%	3,215.6	22.2%	-16.0%	6,880.1	21.6%
Тах	173.8	1.1%	585.2	4.0%	-70.3%	(1,486.6)	-4.7%
PAT	2,528.2	15.9%	2,630.4	18.2%	-3.9%	8,366.7	26.2%
Non controlling interest	(51.9)	-0.3%	(0.2)	0.0%	-100.0%	(23.2)	-0.1%
Profit for the Period	2,580.1	16.3%	2,630.6	18.2%	-1.9%	8,389.9	26.3%
Adjusted PAT	3,454.2	21.8%	3,829.4	26.4%	-9.8%	8,544.1	26.8%

*Adjusted PAT = Reported PAT + Exceptional Items + Amortization of Kesh King & other brand related intangible assets. For FY22, it also excludes, MAT credit entitlement of previous years

Balance Sheet



SI.	Equity & Liabilities	As at 30.09.2022 As at 31.03.2022		sı.	Assats	As at 30.09.2022	As at 31.03.2022
		Unaudited	Audited	51.	Assets	Unaudited	Audited
	EQUITY			1	Non -Current Assets		
(a)	Equity Share capital	441	441	(a)	Property, Plant and Equipment	6,556	6,857
(b)	Other Equity	22,885	20,325	(b)	Capital work-in-progress	35	17
	Total Equity attributable to owners of the Parent	23,326	20,766	(c)	Investment Properties	545	541
(c)	Non-Controlling Interest	107	-23	(d)	Other Intangible Assets	5,205	5,601
	Total Equity	23,433	20,743	(e)	Goodwill on Consolidation	843	242
				(f)	Right of Use Assets	199	198
	LIABILITIES			(g)	Intangible assets under development	6	14
1	Non-Current Liabilities			(h)	Financial Assets		
(a)	Financial Liabilities				(i) Investments		
	(i) Lease Liabilities	100	99		a) Investment in Associates	118	561
	(ii) Other Financial Liabilities	69	69		b) Others	2,100	2,071
(b)	Provisions	303	252		(ii) Loans	21	48
(c)	Deferred Tax Liabilities (Net)	144	75		(iii) Other Financial Assets	882	767
(d)	Other Non-Current Liabilities	170	179	(i)	Deferred Tax Assets (net)	3,131	2,838
				(j)	Other Non-Current Assets	66	93
		786	675			19,707	19,847
2	Current liabilities						
(a)	Financial Liabilities			2	Current assets		
	(i) Borrowings	790	2,637	(a)	Inventories	3,784	3,576
	(ii) Lease Liabilities	85	80	(b)	Financial Assets		
	(ii) Trade Payables				(i) Investments	1,109	395
	Total oustanding dues of Micro & Small Enterprises	289	337		(ii) Trade Receivables	3,501	3,209
	Total oustanding dues of creditors Other than Micro & Small Enterpri	3,910	3,750		(iii) Cash & Cash Equivalents	377	276
	(iii) Other Financial Liabilities	771	585		(iv) Bank Balances other than (iii) above	1,010	884
(b)	Other Current Liabilities	366	254		(v) Loans	64	38
(c)	Provisions	1,159	1,344		(vi) Other Financial Assets	286	457
(d)	Current Tax Liabilities (Net)	147	170	(c)	Current Tax Assets (Net)	17	9
				(d)	Other Current Assets	1,879	1,884
		7,516	9,157			12,027	10,728
	Total Equity and Liabilities	31,734	30,575		Total Assets	31,734	30,575

Net Cash of Rs. 181 crore

Awards & Accolades





<text><text><section-header><text><text><text><text><text><text>

Certificate

BoroPlus felicitated as one of the 'Iconic Brands of India' at the 5th edition of "The Economic Times Iconic Brands of India" Emami's manufacturing unit at Pacharia awarded as "Greentech Environment Award 2022"- for two times in a row .



Thank you